US court rules in favor of Celltrion and Hospira in Remicade patent ruling
US healthcare giant Johnson & Johnson (NYSE: JNJ) has confirmed a negative US court ruling relating to a biosimilar version of its blockbuster rheumatoid arthritis drug Remicade (infliximab).
The District of Massachusetts Federal Court has issued a ruling on a summary judgment motion filed by South Korea’s Celltrion (Kosdaq: 068270) and Hospira, a subsidiary of Pfizer (NYSE: PFE), in the infringement lawsuits related to Remicade filed by J&J’s subsidiary Janssen Biotech, finding that US patent No 6,284,471 for the drug is invalid.
The drug's patent was scheduled to lapse in September 2018. Celltrion and Hospira's infliximab biosimilar, trade name Inflectra, received US Food and Drug Administration approval in April this year. Inflectra is already marketed by Hospira in Europe (since February 2015), as well as in Australia and Canada.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze